+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Adcirca

  • ID: 4775231
  • Report
  • 15 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO). The extracellular vasodilator NO activates cellular guanylate cyclase, which in turn increases cyclic guanosine monophosphate (cGMP) concentrations, leading to smooth muscle cell vasorelaxation. PDE5 rapidly degrades cGMP, and by inhibiting the cGMP-specific PDE5 enzyme, Adcirca inhibits the degradation of cGMP, which enhances NO-induced vasodilation (Barnett and Machado, 2006).

Analyst Outlook
Adcirca (tadalafil; Eli Lilly/United Therapeutics/Nippon Shinyaku) now faces generic competition across the US and five major EU markets (France, Germany, Italy, Spain, and the UK). While Adcirca’s historical sales have exceeded the first-to-market phosphodiesterase 5 (PDE5) inhibitor Revatio (sildenafil; Pfizer), generic competition in the US from 2018 will significantly erode Adcirca’s sales. Conversely, continued uptake of PDE5 inhibitors in combination with endothelin receptor antagon.(ERAs) based on the AMBITION trial will act as an opposing force, offsetting some of the losses.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Adcirca : Pulmonary hypertension

LIST OF FIGURES
Figure 1: Adcirca for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of Adcirca for pulmonary hypertension
Figure 3: The authors drug assessment summary of Adcirca for pulmonary hypertension
Figure 4: Adcirca sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: Adcirca drug profile
Table 2: Adcirca pivotal trial data in pulmonary hypertension
Table 3: Adcirca sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll